Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

NCT ID: NCT00055978

Last Updated: 2011-06-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 112 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-10-31
• Study Completion Date: 2009-05-31

Brief Summary

RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing the development or recurrence of lung cancer in former heavy smokers.

PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing the development or recurrence of lung cancer in former heavy smokers who are at risk of developing cancer.

Detailed Description

OBJECTIVES:

• Determine the feasibility of chemoprevention of lung cancer with celecoxib in former heavy smokers at risk for developing primary or second primary lung cancer.
• Determine the safety and side effects of this drug in these patients.
• Determine the quality of life of patients treated with this drug.
• Determine the role of COX-2-specific inhibitors (e.g., celecoxib) on antitumor immunity within the lung microenvironment of these patients.
• Determine the effects of COX-2 inhibition on angiogenesis in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to presence of preinvasive lesions (yes vs no). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral placebo twice daily for 6 months.
• Arm II: Patients receive oral celecoxib twice daily for 6 months. Treatment in both arms continues in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed every 6 months during treatment and then annually for up to 4 years.

Patients are followed annually for up to 4 years.

PROJECTED ACCRUAL: A total of 180 patients (90 per treatment arm) will be accrued for this study.

Conditions

Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Arm I

Patients receive oral placebo twice daily for 6 months.

Group Type: EXPERIMENTAL

placebo

Intervention Type: OTHER

Given orally

Arm II

Patients receive oral celecoxib twice daily for 6 months.

Group Type: EXPERIMENTAL

celecoxib

Intervention Type: DRUG

Given orally. 400mg twice daily for 6 months.

Interventions

celecoxib

Given orally. 400mg twice daily for 6 months.

Intervention Type: DRUG

placebo

Given orally

Intervention Type: OTHER

Other Intervention Names

Celebrex; Celebra

Eligibility Criteria

Inclusion Criteria

• Heavy former smokers without prior history of NSCLC

• Age > 45
• Smoked for minimum of 30 pack years
• Former smokers with prior curative resection of surgical stage I NSCLC will be recruited and must be:

• Age > 18
• Smoked > 10 pack years
• Must have had pathological staging and the extent of disease documented. At least one nodal station each must have been biopsied and all biopsies must have been negative
• At least 6 months post curative resection of Stage I prior NSCLC, without evidence for recurrence or second primary lung cancer
• Normal blood chemistry and cell counts
• Negative pregnancy test

Exclusion Criteria

• Framingham 10-year-risk for coronary artery disease score > 10%
• History of cardiovascular disease
• Evidence of diffuse coronary calcification on screening CT
• Concurrent use of NSAIDs. The use of cardiac (baby) Aspirin is permitted
• Hypersensitivity to celecoxib, sulfonamides, aspirin or other NSAIDs
• Liver dysfunction [abnormally elevated liver function tests [transaminases (ALT, AST) > ULN, alkaline phosphatase (ALKP) > 1.5 ULN]] or history of cirrhosis
• No peptic ulcer disease (PUD) diagnosis nor active symptoms in the last 2 years or, if PUD was diagnosed < 2 years, there must be no active symptoms, and endoscopic confirmation of healing
• Renal dysfunction [abnormally elevated blood urea nitrogen (BUN) > 1.5 ULN and creatinine > ULN]
• End state respiratory disease
• Unstable angina or a history of significant coronary artery disease
• Other malignancies excluding non-melanoma type skin cancer and in situ cervical cancer. Persons with stage I/II head and neck cancer must be disease free for at least 12 months
• Pregnancy
• Lactation
• Unwillingness to practice contraception
• On systemic corticoid steroid therapy
• Coagulopathy
• Use of Coumadin
• Concurrent use of medication know to alter or be affected by alteration of hepatic p450 2C9 enzymes.
• Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
• Patients who had received photosensitizing agents such as hematoporphyrin derivative or chemopreventive drugs such as retinoids within 3 months prior to the bronchoscopic procedure, radiotherapy to the chest, or cytotoxic chemotherapy agents
• Subject found to have CIS during screening bronchoscopy will be treated with local therapy prior to randomization

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Jonsson Comprehensive Cancer Center at UCLA

Principal Investigators

Jenny T. Mao, MD

Role: PRINCIPAL_INVESTIGATOR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California, United States

Countries

United States

Other Identifiers

U01CA096134

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA016042

Identifier Type: NIH

Identifier Source: secondary_id

View Link

UCLA-0108074

Identifier Type: -

Identifier Source: secondary_id

CDR0000271912

Identifier Type: -

Identifier Source: org_study_id